martes, 6 de octubre de 2026
BuscarExplore
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· November 20, 2025

Netflix (NFLX) Down 1.5% Since Last Earnings Report: Can It Rebound?

View original at finance.yahoo.com
Netflix (NFLX) Down 1.5% Since Last Earnings Report: Can It Rebound? It has been about a month since the last earnings report for Netflix (NFLX)…
Opening lines of the source · short snapshot — read the full document at the original

Lo que extrajimos de esta fuente

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Netflix does not expect the Brazilian tax matter to have a material impact on future results

    80% confidence
  • Absent the Brazilian tax expense, Netflix would have exceeded its third-quarter operating margin forecast

    80% confidence
  • Total viewing hours grew faster in the third quarter than in the first half of 2025

    80% confidence
  • Netflix is on track to more than double ad revenues in 2025, albeit from a relatively small base

    80% confidence
  • Netflix achieved its highest quarterly viewing share ever in both the United States and the United Kingdom in Q3 2025

    80% confidence
  • Netflix has a Zacks Rank #4 (Sell) and analysts expect a below average return from the stock in the next few months

    80% confidence
  • In the fourth quarter, Netflix is using AI to test new ad formats to generate the most relevant ad creative and placement for members, and for faster development of media plans

    80% confidence
  • These AI advancements will enable Netflix to test, iterate, and innovate on dozens of ad formats by 2026

    80% confidence
  • The earnings shortfall was primarily attributed to a one-time $619 million expense related to an ongoing dispute with Brazilian tax authorities

    80% confidence
Lo que sabemos · la inteligencia detrás de esta página
En vivo desde el sustrato
Lo que estamos viendo
Obesity and Immunology Readouts, Big Pharma M&A and AI-Designed Drugs Converge Into a Q4 2026 Catalyst Wave
Late-stage data and deal activity are clustering ahead of Q4 2026. Novo Nordisk's CagriSema won Best Abstract at EASD 2026 for its brain and body (fMRI/MRI) data, Lilly showed ADtouch results for EBGLYSS and agreed to buy Merida Biosciences for $2.9B, and Merck's tulisokibart hit its Phase 2b endpoints. A key regulatory catalyst follows: the FDA PDUFA date for the ivonescimab BLA on 2026-11-14. AI-designed rentosertib showing anti-aging effects adds a speculative AI-drug-discovery thread, while QAIAx's microcities trial and QIII pilot (planned 2027-01-01) are peripheral, forecast-only items.
Nuestra lectura de los datos ›
Señales que seguimos
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patrones que observamos ›
Donde las fuentes discrepan
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Señalamos los conflictos abiertamente ›
Verificado recientemente
✓ Verificado con la fuente original
4,985
hechos rastreados a su fuente — y señalamos los que no se sostienen.
101 entidades seguidas4,985 hechos verificados con la fuente5,351 documentos fuente archivados
Consulta estos datos → isubstrate.com